H.C. Wainwright raised the firm’s price target on Terns Pharmaceuticals (TERN) to $60 from $20 and keeps a Buy rating on the shares. The firm says the updated Phase 1 CARDINAL data for TERN-701 reinforced that its emerging efficacy profile materially exceeds what is achievable with current BCR ABL1 inhibitors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TERN:
- Terns Pharmaceuticals files automatic mixed securities shelf
- Terns Pharmaceuticals price target raised to $56 from $36 at Barclays
- Promising Potential of TERN-701: A Strong Contender in the CML Treatment Landscape
- Terns Pharmaceuticals Unveils Promising Phase 1 Trial Data
- Terns Parmaceuticles trading resumes